Australian Women's Health Focus Drives VMS Demand, Investment in RWE for Differentiation
The Australian Government's declaration of women's health as a national priority, coupled with strong consumer preference for VMS over pharmaceuticals, is creating significant market expansion. H&H Group highlights unmet needs and the strategic importance of real-world evidence (RWE) for product differentiation and TGA-compliant claims.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
H&H Group's insights from the Growth Asia Summit 2026 underscore a substantial, yet underserved, market for women's health supplements, particularly in Australia. Dr. Novita Puspasari, Scientific Affairs Manager at H&H Group, noted that 40% of Australian women lack understanding regarding perimenopause and menopause, yet prefer vitamins, minerals, and supplements (VMS) over prescription medicines or Hormone Replacement Therapy (HRT). This preference, coupled with the fact that women influence approximately 80% of healthcare spending, presents a clear commercial opportunity for supplement manufacturers.
The market is further buoyed by a shifting societal narrative, with mainstream media and social platforms destigmatising women's health issues. This increased awareness is driving demand for credible, effective, and science-backed solutions. The Australian Government's 2025 declaration of women's health as a 'national priority' confirms this trend, promising greater investment and initiatives to improve care and close knowledge gaps among healthcare practitioners. This governmental backing validates the sector's growth trajectory and elevates women's health from a niche concern to a core health focus.
H&H Group's proprietary research involving 778 Australian women aged 20+ confirms strong consumer interest, with one in three expressing consideration for women's health supplements. The study found women are significantly more likely than men (47% vs. 18%) to recognise the benefits of VMS for hormonal balance, with peak interest among those aged 35-54. This data directs product development towards targeted solutions for hormonal health, menstrual support, and menopausal symptoms.
Crucially, H&H Group is investing in Real-World Evidence (RWE) research, aligning with the Therapeutic Goods Administration (TGA) definition. While randomised controlled trials (RCTs) establish efficacy, RWE provides insights into product effectiveness, consumer perception, and usage patterns in diverse, real-world populations. This approach captures 'softer' outcomes like quality of life and sleep, which are critical for consumer satisfaction but often overlooked in clinical settings. RWE facilitates continuous feedback, informs product development, and enables differentiation through credible, TGA-permitted 'felt benefits' beyond on-pack claims.
What this means for Australia
Australian manufacturers and brand owners must prioritise R&D into targeted women's health formulations, leveraging the strong consumer preference for VMS. Compliance with TGA guidelines for RWE will be crucial for substantiating 'felt benefit' claims, providing a competitive edge beyond traditional efficacy data. Procurement leads should anticipate increased demand for ingredients supporting hormonal balance, menopause, and menstrual health, necessitating proactive supply chain management to secure high-quality, traceable raw materials. Regulatory teams must monitor evolving TGA guidance on RWE and claims substantiation, ensuring all new product launches meet strict compliance standards. Strategic investment in educational marketing can also capture market share by addressing the 40% knowledge gap in perimenopause/menopause.
For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.